CLOS
GNOM icon

Compagnie Lombard Odier SCmA’s Global X Genomics & Biotechnology ETF GNOM Stock Holding History

Compagnie Lombard Odier SCmA’s Portfolio GNOM Stock Details GNOM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-875
Closed -$69K – 627
2021
Q4 		$69K Buy
+875
New +$73.5K ﹤0.01% 474

Other funds holding GNOM

PAG
Private Advisor Group Morristown, New Jersey $21.3B AUM 22.13% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
MIG
McGuire Investment Group Wakefield, Rhode Island $885M AUM 47.78% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
OCM
One Capital Management Westlake Village, California $3.65B AUM 15.32% 1-Year Est. Return
MML Investors Services
MML Investors Services Springfield, Massachusetts $36.1B AUM 19.68% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
EWM
Elmwood Wealth Management Berkeley, California $400M AUM 17.81% 1-Year Est. Return

Compagnie Lombard Odier SCmA's GNOM Position: Q1 2022 in Review

Compagnie Lombard Odier SCmA sold out of Global X Genomics & Biotechnology ETF (GNOM) in Q1 2022, closing a stake of 875 shares — an estimated $69K sold.

Compagnie Lombard Odier SCmA first reported a position in GNOM in Q4 2021 and held it in 1 quarter. The position peaked at $69K in Q4 2021. 60 funds tracked by Wall St. Rank hold GNOM as of Q1 2022.

  • Compagnie Lombard Odier SCmA reported no remaining Global X Genomics & Biotechnology ETF position as of Q1 2022 after selling out during the quarter.
  • Compagnie Lombard Odier SCmA sold 875 Global X Genomics & Biotechnology ETF shares in Q1 2022, an estimated $69K.
  • Compagnie Lombard Odier SCmA first reported a position in Global X Genomics & Biotechnology ETF in Q4 2021 and held it in 1 quarter.
  • Compagnie Lombard Odier SCmA's Global X Genomics & Biotechnology ETF position peaked at $69K in Q4 2021.
  • 60 funds tracked by Wall St. Rank held Global X Genomics & Biotechnology ETF as of Q1 2022.

Based on Compagnie Lombard Odier SCmA's 13F filing for Q1 2022, filed 27 Apr 2022.